Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
102 hedge funds and large institutions have $124M invested in Paratek Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 31 increasing their positions, 33 reducing their positions, and 23 closing their positions.
45% more call options, than puts
Call options by funds: $798K | Put options by funds: $550K
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
6% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 33
9% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 23
3% less funds holding
Funds holding: 105 → 102 (-3)
48% less capital invested
Capital invested by funds: $238M → $124M (-$114M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$5.83M |
| 2 |
FI
Fosun International
Hong Kong,
China
|
+$1.73M |
| 3 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
+$1.51M |
| 4 |
Renaissance Technologies
New York
|
+$982K |
| 5 |
APCM
Arbiter Partners Capital Management
New York
|
+$910K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.89M |
| 2 |
Man Group
London,
United Kingdom
|
-$2.01M |
| 3 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$1.99M |
| 4 |
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
|
-$1.48M |
| 5 |
Boston Partners
Boston,
Massachusetts
|
-$1.09M |
PRTK Hedge Fund Activity: Q4 2018 in Review
102 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q4 2018, worth a combined $124M — down 48% from $238M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of PRTK and 21 opened new positions — a net loss of 2 holders — while 33 trimmed existing stakes and 31 added.
The largest buyer was Armistice Capital, adding an estimated $5.83M. The largest seller was Vanguard Group, cutting an estimated $5.89M.
- 102 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q4 2018, down from 105 in Q3 2018.
- Funds reported $124M of Paratek Pharmaceuticals, Inc. stock for Q4 2018, down 48% quarter-over-quarter.
- 21 funds opened new Paratek Pharmaceuticals, Inc. positions in Q4 2018 and 23 closed out, a net change of -2 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q4 2018 was Armistice Capital, an estimated $5.83M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q4 2018 was Vanguard Group, an estimated $5.89M sold.
Based on aggregated 13F filings for Q4 2018.